RIPK1 inhibition enhances the therapeutic efficacy of chidamide in FLT3-ITD positive AML, both in vitro and in vivo

References

• Daver N, Schlenk RF, Russell NH, et al. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299–312.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221.
   PubMed Web of Science ®Google Scholar
• Sasaki K, Kantarjian HM, Kadia T, et al. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer. 2019;125(21):3755–3766.
   PubMed Web of Science ®Google Scholar
• Tarlock K, Pollard JA, Alonzo TA, et al. Response to sorafenib in FLT3/ITD AML is dependent on co-occurring mutational profile. Blood. 2019;134(Suppl. 1):119.
   Google Scholar
• Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study. Lancet Oncol. 2017;18(8):1061–1075.
   PubMed Web of Science ®Google Scholar
• Fleischmann M, Schnetzke U, Schrenk KG, et al. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. J Cancer Res Clin Oncol. 2017;143(2):337–345.
   PubMed Web of Science ®Google Scholar
• Konig H, Levis M. Targeting FLT3 to treat leukemia. Expert Opin Ther Targets. 2015;19(1):37–54.
   PubMed Web of Science ®Google Scholar
• Shoukier M, Kadia T, Konopleva M, et al. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer. 2021;127(3):381–390.
   PubMed Web of Science ®Google Scholar
• Bezerra MF, Lima AS, Pique-Borras MR, et al. Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis. Blood. 2020;135(11):870–875.
   PubMed Web of Science ®Google Scholar
• Lee L, Hizukuri Y, Severson P, et al. A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia. Haematologica. 2021;106(4):1022–1033.
   PubMed Web of Science ®Google Scholar
• Long J, Jia MY, Fang WY, et al. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD + acute myeloid leukemia. Blood. 2020;135(17):1472–1483.
   PubMed Web of Science ®Google Scholar
• Khoury MK, Gupta K, Franco SR, et al. Necroptosis in the pathophysiology of disease. Am J Pathol. 2020;190(2):272–285.
   PubMed Web of Science ®Google Scholar
• Yuan J, Amin P, Ofengeim D. Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases. Nat Rev Neurosci. 2019;20(1):19–33.
   PubMed Web of Science ®Google Scholar
• Alvarez-Diaz S, Preaudet A, Samson AL, et al. Necroptosis is dispensable for the development of inflammation-associated or sporadic colon cancer in mice. Cell Death Differ. 2021;28(5):1466–1476.
   PubMed Web of Science ®Google Scholar
• Jiao D, Cai Z, Choksi S, et al. Necroptosis of tumor cells leads to tumor necrosis and promotes tumor metastasis. Cell Res. 2018;28(8):868–870.
   PubMed Web of Science ®Google Scholar
• Pandolfi F, Altamura S, Frosali S, et al. Key role of DAMP in inflammation, cancer, and tissue repair. Clin Ther. 2016;38(5):1017–1028.
   PubMed Web of Science ®Google Scholar
• Seifert L, Werba G, Tiwari S, et al. The necrosome promotes pancreatic oncogenesis via CXCL1 and mincle-induced immune suppression. Nature. 2016;532(7598):245–249.
   PubMed Web of Science ®Google Scholar
• Ghosh D, Dawson MR. Microenvironment influences cancer cell mechanics from tumor growth to metastasis. Adv Exp Med Biol. 2018;1092:69–90.
   PubMed Web of Science ®Google Scholar
• Strilic B, Yang L, Albarran-Juarez J, et al. Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis. Nature. 2016;536(7615):215–218.
   PubMed Web of Science ®Google Scholar
• Sung SY, Hsieh CL, Wu D, et al. Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. Curr Probl Cancer. 2007;31(2):36–100.
   PubMed Web of Science ®Google Scholar
• Degterev A, Hitomi J, Germscheid M, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol. 2008;4(5):313–321.
   PubMed Web of Science ®Google Scholar
• Xin J, You D, Breslin P, et al. Sensitizing acute myeloid leukemia cells to induced differentiation by inhibiting the RIP1/RIP3 pathway. Leukemia. 2017;31(5):1154–1165.
   PubMed Web of Science ®Google Scholar
• Degterev A, Huang Z, Boyce M, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005;1(2):112–119.
   PubMed Web of Science ®Google Scholar
• Li Y, Xiong Y, Zhang G, et al. Identification of 5-(2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as a new class of receptor-interacting protein kinase 1 (RIPK1) inhibitors, which showed potent activity in a tumor metastasis model. J Med Chem. 2018;61(24):11398–11414.
   PubMed Web of Science ®Google Scholar
• Gao S, Li X, Zang J, et al. Preclinical and clinical studies of chidamide (CS055/HBI-8000), an orally available subtype-selective HDAC inhibitor for cancer therapy. Anticancer Agents Med Chem. 2017;17(6):802–812.
   PubMed Web of Science ®Google Scholar
• Shi Y, Jia B, Xu W, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol. 2017;10(1):69.
   PubMedGoogle Scholar
• Shi Y, Dong M, Hong X, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26(8):1766–1771.
   PubMed Web of Science ®Google Scholar
• Zhao S, Guo J, Zhao Y, et al. Chidamide, a novel histone deacetylase inhibitor, inhibits the viability of MDS and AML cells by suppressing JAK2/STAT3 signaling. Am J Transl Res. 2016;8(7):3169–3178.
   PubMed Web of Science ®Google Scholar
• Li Y, Chen K, Zhou Y, et al. A new strategy to target acute myeloid leukemia stem and progenitor cells using chidamide, a histone deacetylase inhibitor. Curr Cancer Drug Targets. 2015;15(6):493–503.
   PubMed Web of Science ®Google Scholar
• Li X, Yan X, Guo W, et al. Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine. Biomed Pharmacother. 2017;90:699–704.
   PubMed Web of Science ®Google Scholar
• Vanlangenakker N, Bertrand MJ, Bogaert P, et al. TNF-induced necroptosis in L929 cells is tightly regulated by multiple TNFR1 complex I and II members. Cell Death Dis. 2011;2:e230.
   PubMed Web of Science ®Google Scholar
• Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell. 2008;133(4):693–703.
   PubMed Web of Science ®Google Scholar
• Safferthal C, Rohde K, Fulda S. Therapeutic targeting of necroptosis by Smac mimetic bypasses apoptosis resistance in acute myeloid leukemia cells. Oncogene. 2017;36(11):1487–1502.
   PubMed Web of Science ®Google Scholar
• Brumatti G. The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia. Sci Transl Med. 2017;8(339):339ra69.
   Web of Science ®Google Scholar
• De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441.
   PubMed Web of Science ®Google Scholar
• Santos FP, Jones D, Qiao W, et al. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer. 2011;117(10):2145–2155.
   PubMed Web of Science ®Google Scholar
• Ning ZQ, Li ZB, Newman MJ, et al. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 2012;69(4):901–909.
   PubMed Web of Science ®Google Scholar
• Chen K, Yang Q, Zha J, et al. Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia. Cell Death Dis. 2020;11(9):778.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Kepp O, Chan FK, et al. Necroptosis: mechanisms and relevance to disease. Annu Rev Pathol. 2017;12:103–130.
   PubMed Web of Science ®Google Scholar
• Declercq W, Vanden Berghe T, Vandenabeele P. RIP kinases at the crossroads of cell death and survival. Cell. 2009;138(2):229–232.
   PubMed Web of Science ®Google Scholar
• Wang Z, Guo LM, Zhou HK, et al. Using drugs to target necroptosis: dual roles in disease therapy. Histol Histopathol. 2018;33(8):773–789.
   PubMed Web of Science ®Google Scholar
• Wang T, Jin Y, Yang W, et al. Necroptosis in cancer: an angel or a demon? Tumour Biol. 2017;39(6):1010428317711539.
   Google Scholar
• Han W, Xie J, Fang Y, et al. Nec-1 enhances shikonin-induced apoptosis in leukemia cells by inhibition of RIP-1 and ERK1/2. Int J Mol Sci. 2012;13(6):7212–7225.
   PubMed Web of Science ®Google Scholar
• Lin L, Que Y, Lu P, et al. Chidamide inhibits acute myeloid leukemia cell proliferation by lncRNA VPS9D1-AS1 downregulation via MEK/ERK signaling pathway. Front Pharmacol. 2020;11:569651.
   PubMed Web of Science ®Google Scholar
• Dong M, Ning ZQ, Xing PY, et al. Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. Cancer Chemother Pharmacol. 2012;69(6):1413–1422.
   PubMed Web of Science ®Google Scholar
• Wang L, Luo J, Chen G, et al. Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study. Clin Epigenet. 2020;12(1):132.
   PubMed Web of Science ®Google Scholar